A phase Ib/IIa trial of panobinostat in combination with trastuzumab in adult female patients with HER2 [human epidermal growth factor receptor 2] positive metastatic breast cancer whose disease has progressed during or following therapy with trastuzumab.

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Panobinostat (Primary) ; Panobinostat (Primary) ; Trastuzumab
Indications Advanced breast cancer
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals

Most Recent Events

02 Jul 2019 The trial is completed at France (End Date: 02 May 2011), as per European Clinical Trials Database record.
04 Apr 2016 Status changed from completed to discontinued due to insufficient evidence of clinical benefit.
24 Mar 2012 Additional location (United Kingdom) added as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight